Vikram Purohit
Stock Analyst at Morgan Stanley
(1.79)
# 3,371
Out of 5,111 analysts
161
Total ratings
31.25%
Success rate
-7.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: Equal-Weight | $86 → $92 | $98.64 | -6.73% | 25 | Dec 8, 2025 | |
| CMPS COMPASS Pathways | Maintains: Overweight | $10 → $11 | $6.59 | +66.92% | 2 | Nov 5, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $31 → $34 | $32.59 | +4.33% | 3 | Oct 28, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $80 → $79 | $63.45 | +24.51% | 11 | Oct 20, 2025 | |
| ABSI Absci | Maintains: Overweight | $6.4 → $5.89 | $3.39 | +73.75% | 3 | Aug 18, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $4.20 | +19.05% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $213.24 | +17.24% | 19 | May 5, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $146.24 | +29.92% | 19 | Feb 27, 2025 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $4.37 | +105.95% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $31.57 | -1.81% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $16 | $117.91 | -86.43% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $28.95 | -65.46% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $8.34 | -28.06% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $13.83 | +203.69% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $85.68 | -52.15% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $11.12 | +259.71% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $2.08 | +525.00% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $18.21 | +108.68% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $8.74 | +128.83% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $17.77 | -43.73% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $0.96 | +2,185.00% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $18.29 | +9.35% | 2 | Aug 5, 2020 |
Incyte
Dec 8, 2025
Maintains: Equal-Weight
Price Target: $86 → $92
Current: $98.64
Upside: -6.73%
COMPASS Pathways
Nov 5, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $6.59
Upside: +66.92%
Zenas BioPharma
Oct 28, 2025
Maintains: Overweight
Price Target: $31 → $34
Current: $32.59
Upside: +4.33%
Halozyme Therapeutics
Oct 20, 2025
Maintains: Overweight
Price Target: $80 → $79
Current: $63.45
Upside: +24.51%
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4 → $5.89
Current: $3.39
Upside: +73.75%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $4.20
Upside: +19.05%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $213.24
Upside: +17.24%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $146.24
Upside: +29.92%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $4.37
Upside: +105.95%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $31.57
Upside: -1.81%
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $117.91
Upside: -86.43%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $28.95
Upside: -65.46%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $8.34
Upside: -28.06%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $13.83
Upside: +203.69%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $85.68
Upside: -52.15%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $11.12
Upside: +259.71%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $2.08
Upside: +525.00%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $18.21
Upside: +108.68%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $8.74
Upside: +128.83%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $17.77
Upside: -43.73%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $0.96
Upside: +2,185.00%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $18.29
Upside: +9.35%